在实验性大鼠模型中,L-卡尼丁逆转了甲基酸诱导的毒性:关于SIRT1/PGC-1α/Nrf2/HO-1轴的洞察
Sara M Radwan1, Mustafa Alqulaly2, Magdy Y Elsaeed2
1Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Journal of applied toxicology : JAT
|June 14, 2023
概括
L-卡尼丁 (LC) 保护脏免受化学疗法药物甲索特雷克萨特 (MTX) 造成的脏损伤. 液晶蛋白减少了脏中的氧化应激,炎症和细胞死亡,提供了潜在的保护补充剂.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 甲甲酸 (MTX) 是一种重要的化疗剂和免疫抑制剂.
- 由于剂量依赖性毒性,MTX的使用经常受到限制.
- 确定减轻MTX诱导的损伤的策略至关重要.
研究的目的:
- 调查L-卡尼丁 (LC) 对MTX诱导的毒性的保护作用.
- 为了阐明LC的保护作用的潜在机制.
主要方法:
- 雄性斯普拉格-道利大鼠被给予MTX (20 mg/kg) 和/或LC (500 mg/kg).
- 功能通过组织病理学,氧化应激标志物 (MDA,SOD),炎症标志物 (TNF-α,IL-6) 和亡标志物 (Bax,Bcl2,caspase-3) 来评估.
- 量化了SIRT1,PGC-1α,Nrf2和HO-1的蛋白质水平.
主要成果:
- LC显著改善了MTX诱导的体病理性损伤.
- 液结合治疗减少了MTX诱导的脏组织中的氧化应激,炎症和亡.
- LC可提高SIRT1,PGC-1α,Nrf2和HO-1信号通路的表达.
结论:
- L-卡尼丁对MTX诱导的毒性具有显著的保护作用.
- 液体细胞的保护机制包括通过SIRT1/PGC-1/Nrf2/HO-1通路的抗氧化,抗炎和抗亡活性.
- 补充LC可能是一个可行的策略,以防止MTX治疗的不良脏副作用.
更多相关视频
相关概念视频
Electron Transport Chain: Complex I and II
14.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.6K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
271
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
271


